A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4614 participants.
Also called NCT02415400
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose other
- Phase
- Phase 4
- Enrolled
- 4,614 participants
- Registry
-
NCT02415400 -
2014-002004-24
-
- Other papers using this trial's data
- Antithrombotic Strategies According to Age: Insights from the AUGUSTUS Trial
- Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-Way Comparison From AUGUSTUS
- Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
- Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention
- Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial
- Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS
- Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial
- Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS
- Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial
- Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, France, Germany, Hungary, India, Israel, Italy, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Korea, Spain, Sweden, Switzerland, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02415400. Randomized; no masking; primary purpose other. Start 2015-06-04 (actual); primary completion 2018-11-10 (actual). Results posted on 2020-02-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
- Condition
- Acute Coronary Syndromes
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- vitamin K antagonist
- Intervention (Drug)
- Acetylsalicylic acid
- Intervention (Other)
- Acetylsalicylic acid placebo
- Lead sponsor
- Bristol-Myers Squibb
- Collaborator
- Pfizer
- Collaborator
- Duke Clinical Research Institute
Record details
- Record id
cardio:ct-nct02415400- Content hash
9562f7c4475d9cf002c6d1bfbc5ed8ca33826ee901046f646fcbae2cd25e7128